Search results
Results from the WOW.Com Content Network
Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. [1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. [1]
It seems that months of contentious merger talks between French pharmaceutical company Sanofi-Aventis (SNY) and U.S. biotech Genzyme (GENZ) have entered the home stretch. Sanofi is expected to ...
After months of courting U.S. drugmaker Genzyme (GENZ), French pharmaceutical company Sanofi-Aventis (SNY) launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all ...
Sanofi-Aventis (SNY) CEO Chris Viehbacher (pictured) said in a webcast Wednesday he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme (GENZ) at a ...
By 2015, Recursion had closed its Series A round of funding and signed a research agreement with Sanofi Genzyme. [14] In 2020, the company received $50 million equity investment from Bayer during its Series D funding round. [15] [16] The company listed on the Nasdaq Stock Exchange on April 20, 2021 under the ticker symbol RXRX.
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right ...